Back to top

cancer: Archive

Kinjel Shah

Investing in Oncology: 3 Cancer Stocks With Promising Pipelines

Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.

BMYPositive Net Change PFENegative Net Change LLYNegative Net Change ABBVPositive Net Change ALLONegative Net Change RLAYPositive Net Change PYXSPositive Net Change

Kinjel Shah

Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?

MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth.

AZNNegative Net Change MRKPositive Net Change SMMTNegative Net Change

Kinjel Shah

Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025

J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.

AZNNegative Net Change NVSNegative Net Change JNJPositive Net Change PFENegative Net Change LLYNegative Net Change ABBVPositive Net Change ALLONegative Net Change

Urmimala Biswas

TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now?

GH gains ground with stronger guidance, improving margin and Reveal's breakout as TEM scales fast but stays unprofitable.

AZNNegative Net Change GHPositive Net Change TEMNegative Net Change

Ekta Bagri

Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?

Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.

BMYPositive Net Change PFENegative Net Change

Sundeep Ganoria

CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?

CRSP surges 14% on encouraging CTX310 data and growing Casgevy sales, despite early-stage pipeline risks.

VRTXNegative Net Change BEAMNegative Net Change NTLAPositive Net Change CRSPPositive Net Change

Kinjel Shah

Top Cancer Stocks to Supercharge Your 2025 Portfolio

Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.

AZNNegative Net Change NVSNegative Net Change BMYPositive Net Change PFENegative Net Change LLYNegative Net Change ABBVPositive Net Change FATENegative Net Change

Ekta Bagri

Amgen vs Bristol Myers: Which Biotech Giant Has Better Prospects?

At current levels, we believe AMGN scores above BMY, buoyed by solid fundamentals and recent positive estimate revisions.

BMYPositive Net Change AMGNNegative Net Change

Sundeep Ganoria

Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings

Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.

JAZZNegative Net Change AMRXNegative Net Change

Ekta Bagri

Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?

At current levels, we believe GILD scores above BMY, buoyed by solid fundamentals, potential approval of lenacapavir for HIV prevention, and recent positive estimate revisions.

BMYPositive Net Change MRKPositive Net Change GILDNegative Net Change